drugset
drugset / Trial / NCT00101270

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

NCT00101270 ↗

Phase 1 Completed 24 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of oxaliplatin when given together with irinotecan in treating young patients with refractory solid tumors or lymphomas. Drugs used in chemotherapy, such as oxaliplatin and irinotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Oxaliplatin may help irinotecan kill more cancer cells by making cancer cells more sensitive to the drug. Giving oxaliplatin together with irinotecan may kill more cancer cells.

Timeline

Start
2005-03
Primary completion
2007-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule — Intravenous
Background Irinotecan Small molecule — Intravenous

Indications

Burkitt lymphoma Ewing sarcoma/peripheral primitive neuroectodermal tumor Hodgkins lymphoma cerebellar astrocytoma childhood brain stem glioma childhood central nervous system germ cell tumor childhood cerebral astrocytoma childhood ependymoma childhood kidney neoplasm childhood medulloblastoma colorectal cancer grade III lymphomatoid granulomatosis large-cell immunoblastic lymphoma liver and intrahepatic bile duct neoplasm malignant childhood germ cell neoplasm melanoma nasopharyngeal carcinoma neuroblastoma optic pathway glioma osteosarcoma precursor lymphoblastic lymphoma/leukemia rhabdomyosarcoma supratentorial primitive neuroectodermal tumor